CARPETS
03 Dec 2020
Trial Summary
The main aim of this Phase I study is to assess the safety and immune effects of using autologous peripheral blood T cells in GD2 positive patients being treated with vemurafenib.
Acronym:
CARPETS
ACTRN/NCT /ethics:
ACTRN12613000198729
Scientific title:
Study of increasing doses of genetically modified GD2-specific T cells in patients with metastatic melanoma and refractory solid tumours
Sponsor / Cooperative group:
CALHN
Trial & Patient Characteristics
| Cancer Type | All cancers; Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2013-03-29 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Professor Michael Brown |
| Recruitment Status | Recruiting |
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | - |
| Recruitment Status | Recruiting |